Open AccessGenomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas
Author(s) -
Francesca Menghi,
Kalyan Banda,
Pooja Kumar,
Robert F. Straub,
Lacey E. Dobrolecki,
Isabel V. Rodriguez,
Susan E. Yost,
Harshpreet Chandok,
Marc R. Radke,
George Somlo,
Yuan Yuan,
Michael T. Lewis,
Elizabeth M. Swisher,
Edison T. Liu
Publication year - 2022
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.abn1926
Subject(s) - epigenomics , cancer research , triple negative breast cancer , epigenetics , ovarian cancer , breast cancer , dna methylation , brca mutation , methylation , immunotherapy , medicine , cancer , brca2 protein , immune system , oncology , biology , mutation , immunology , germline mutation , gene , genetics , gene expression
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom